Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Avacta Life Sciences Ltd
Boc Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isar Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Siromics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotides to Inhibit TGFB1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-1021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Latent TGFB1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit TGFB1 for Oncology, Gastrointestil and Genito Uriry System and Sex Hormones Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Camurati-Engelmann Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Idiopathic Pulmory Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC
Nov 06, 2019: Siromics to Present Overview of Company’s Ri Technology Platform at Upcoming Conferences
Nov 05, 2019: Forbius to report phase 1a oncology clinical data with AVID200, first-in-class TGF-beta 1 & 3 inhibitor, in late-breaking poster presentation
Oct 31, 2019: Siromics to present preclinical STP705 data suggesting reduction in Liver Fibrosis at AASLD Liver Meeting
Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Fincing
Sep 28, 2019: ESMO 2019: Forbius demonstrates target engagement in Phase 1 immuno-oncology clinical trial with AVID200, first-in-class TGF-beta 1 & 3 Inhibitor
Sep 23, 2019: Forbius announces AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, to be featured at ESMO and CICON 2019
May 16, 2019: Siromics publishes data for lead candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract
Apr 29, 2019: Forbius’ AVID200, a Novel TGF-beta 1 & 3 inhibitor, cleared by Health Cada to commence phase 1 clinical trial in Solid Tumors
Apr 24, 2019: Forbius: First patient dosed in a phase 1b Myelofibrosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Apr 08, 2019: Siromics to present at World Orphan Drug Congress 2019
Apr 02, 2019: Scholar Rock presents additiol preclinical data demonstrating a highly specific inhibitor of TGF?1 activation can render resistant solid tumors vulnerable to PD1 blockade and drive tumor regression with combition therapy
Mar 12, 2019: Scholar Rock to develop cancer immunotherapy product candidate, SRK-181, a selective inhibitor of TGF?1 activation, to overcome checkpoint inhibitor resistance
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse cutaneous systemic sclerosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse scleroderma trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AlfaSigma SpA, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bonac Corp, H2 2019
Pipeline by Ensol Biosciences Inc, H2 2019
Pipeline by Forbius, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Huabo Biopharm Co Ltd, H2 2019
Pipeline by Isarna Therapeutics GmbH, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Pipeline by Scholar Rock Inc, H2 2019
Pipeline by Sirnaomics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019